2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139327
    CDK12-IN-4
    		Inhibitor
    CDK12-IN-4, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC50 of 0.641 μM at high ATP (2 mM). CDK12-IN-4 has no effect on CDK2/Cyclin E (IC50>20 μM) and CDK9/Cyclin T1 (IC50>20 μM) at high ATP (2 mM) (WO2021116178A1).
    CDK12-IN-4
  • HY-170965
    Anticancer agent 264
    		Inhibitor
    Anticancer agent 264 (Compound 5w) is an anticancer agent that exhibits significant antiproliferative activity across tumor cell lines, with an IC50 range of 7.5-33.67 μM. Anticancer agent 264 significantly induces G2/M phase arrest in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. Anticancer agent 264 reduces the expression of key cell cycle proteins, including CDK1, CDK2, and Cyclin B1, in a dose-dependent manner, and shows strong binding affinity with inhibitor of differentiation (ID) proteins and DNA-binding proteins. Anticancer agent 264 can be used for research in the field of cancer-related diseases.
    Anticancer agent 264
  • HY-E70669
    CDK2/CycA1 Recombinant Human Active Protein Kinase
    CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK2.
    CDK2/CycA1 Recombinant Human Active Protein Kinase
  • HY-155843
    CDK9-IN-25
    		Inhibitor
    CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM).
    CDK9-IN-25
  • HY-E70680
    CDK3/CycO Recombinant Human Active Protein Kinase
    CDK3 is a major player driving retinoblastoma (Rb) phosphorylation during the G0/G1 transition and in the early G1 phase of the cell cycle. CDK3 interacts with various transcription factors involved in cell proliferation, differentiation, and transformation driven by the EGFR/Ras signaling pathway. CDK3/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK3.
    CDK3/CycO Recombinant Human Active Protein Kinase
  • HY-117677
    Cdc7-IN-21
    		Inhibitor
    Cdc7-IN-21 (compound 10c) is a potent and selective Cdc7 inhibitor with an IC50 of 0.07 nM. Cdc7-IN-21 can be used to study cancer.
    Cdc7-IN-21
  • HY-147409
    Ulecaciclib
    		Inhibitor
    Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics.
    Ulecaciclib
  • HY-161463
    CDK2-IN-28
    		Inhibitor
    CDK2-IN-28 (compound 22) is a CDK2 inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM).
    CDK2-IN-28
  • HY-155844
    CDK9-IN-26
    		Inhibitor
    CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC50=0.18 μM). .
    CDK9-IN-26
  • HY-RS02403
    Cdk9 Rat Pre-designed siRNA Set A
    		Inhibitor

    Cdk9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk9 Rat Pre-designed siRNA Set A
  • HY-RS02386
    Cdk5 Rat Pre-designed siRNA Set A
    		Inhibitor

    Cdk5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk5 Rat Pre-designed siRNA Set A
  • HY-173007
    ALK/PI3K/AKT-IN-1
    		Inhibitor
    ALK/PI3K/AKT-IN-1 (Compound 45) inhibits the proliferation of cancer cell A549, H1975 and PC9 with an IC50 of 0.44, 0.83 and 1.51 μM. ALK/PI3K/AKT-IN-1 increases the expression of p21 and p27, inhibits the activity of CDK2 and p-Rb, arrests the cell cycle at G1 phase. ALK/PI3K/AKT-IN-1 inhibits the ALK/PI3K/AKT signaling pathway, promotes the depolarization of mitochondrial membrane potential, and inducing apoptosis in A549 cell. ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheroids.
    ALK/PI3K/AKT-IN-1
  • HY-RS02400
    Cdk8 Rat Pre-designed siRNA Set A
    		Inhibitor

    Cdk8 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk8 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk8 Rat Pre-designed siRNA Set A
  • HY-18629A
    (E/Z)-SU9516
    		Inhibitor
    (E/Z)-SU9516 is the isomer of SU9516 (HY-18629). SU9516 is a potent CDK2 inhibitor，with an IC50 of 22 nM，and also shows inhibitory effects on CDK1 and CDK4，with IC50s of 40，200 nM，respectively.
    (E/Z)-SU9516
  • HY-172128
    NUAK1-IN-2
    		Inhibitor
    NUAK1-IN-2 (Compound 24) is a NUAK1 (IC50 of 3.162 nM) and CDK2/4/6 inhibitor. NUAK1-IN-2 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research.
    NUAK1-IN-2
  • HY-176791
    CDK12-Cyclin K Ligand-Linker Conjugates 1
    		Inhibitor
    CDK12-Cyclin K Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for CDK12-Cyclin K (HY-176790) and a PROTAC linker (HY-W244922), which recruits E3 ligases. CDK12-Cyclin K Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC PP-C8 (HY-144691).
    CDK12-Cyclin K Ligand-Linker Conjugates 1
  • HY-178499
    CDK9-IN-44
    		Inhibitor
    CDK9-IN-44 (Compound 7) is a selective CDK9 inhibitor (IC50=7.6 μM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders.
    CDK9-IN-44
  • HY-113670
    CLK1/2-IN-2
    		Inhibitor 99.31%
    CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC50 values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities[1].
    CLK1/2-IN-2
  • HY-16297R
    Abemaciclib methanesulfonate (Standard)
    		Inhibitor
    Abemaciclib (methanesulfonate) (Standard) is the analytical standard of Abemaciclib (methanesulfonate). This product is intended for research and analytical applications. Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib methanesulfonate (Standard)
  • HY-RS02367
    Cdk16 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk16 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk16 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk16 Mouse Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.